What does this research mean for the field?

Lenvatinib provides significantly better tumor responses and survival benefits than sorafenib as a first-line treatment for unresectable hepatocellular carcinoma, with a comparable incidence of adverse events. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 10, 2022CancersOpen Access

Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

View Full Paper

Ask AI

Bookmark

Authors

SWShijie WangBengbu Medical College YWYiting WangZhengzhou People's Hospital JYJiangtao YuNorth China University of Science and Technology

Discussion

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2022) studied this question.

synapsesocial.com/papers/6aa9281904014c99012638d0 https://doi.org/10.3390/cancers14225525

View Full Paper

Ask AI

Bookmark

November 10, 2022CancersOpen Access

Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

View Full Paper

Ask AI

Bookmark

Authors

SWShijie WangBengbu Medical College YWYiting WangZhengzhou People's Hospital JYJiangtao YuNorth China University of Science and Technology

Discussion

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2022) studied this question.

synapsesocial.com/papers/6aa9281904014c99012638d0 https://doi.org/10.3390/cancers14225525

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark